| Bioactivity | Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis[1]. |
| In Vivo | Efruxifermin (0-100 mg/kg，皮下注射，每周一次，持续4或26周)以剂量依赖的方式减少 Sprague Dawley 大鼠的体重增加[1]。 Animal Model: |
| Name | Efruxifermin |
| CAS | 2375240-92-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tillman EJ, et al. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol. 2022 Apr;179(7):1384-1394. |